Results 71 to 80 of about 26,068 (276)

Mineralocorticoid receptor antagonists in dialysis patients [PDF]

Renal Replacement Therapy, 2016
Mineralocorticoid receptor (MR) antagonists are known to have beneficial effects in patients with cardiovascular disease without renal failure. However, there have been few published studies on the effectiveness of MR antagonists in dialysis patients, and most of the studies were small-sized.
Tawada, Mitsuhiro, Suzuki, Yasuhiro, Sakata, Fumiko, Mizuno, Masashi, Ito, Yasuhiko   +4 more
openaire   +1 more source

Incident heart failure: comparing management and outcome in primary and hospital settings in Western Sweden 2008–2017

ESC Heart Failure, Volume 12, Issue 2, Page 832-838, April 2025.
Abstract Aim Heart failure (HF) is a highly prevalent condition managed in both primary care (PC) and hospital care (HC)‐based settings. HF patients managed in these two settings may differ in their demography, comorbidities and outcomes, so we aimed to compare the patient management in PC and HC in the Västra Götaland Region (VGR) in Sweden.
Xiaojing Chen, Aldina Pivodic, Maria Schaufelberger, Annika Rosengren, Michael Fu   +4 more
wiley   +1 more source

The impact of new tetralogy drugs on ventricular remodeling in heart failure patients: a systematic review and network meta-analysis

BMC Cardiovascular Disorders
Background Heart failure, particularly heart failure with reduced ejection fraction (HFrEF), represents a major global health challenge due to its high prevalence, rapid progression, and substantial mortality rates.
Xi-Wen Wang, Hao Li, Gan-Qi Wang, Ya-Nan Sheng, Xia Wang, Hui Pan, Zhi-Hao Wang, Wei Zhang, Yuan-Yuan Shang, Ming Zhong   +9 more
doaj   +1 more source

Aldosterone Synthase Inhibitors for Cardiorenal Protection: Ready for Prime Time?

Kidney & Blood Pressure Research
Background: Aldosterone is the principal mineralocorticoid hormone and the final effector of the renin-angiotensin-aldosterone system. This hormone is primarily synthesized by the CYP11B2 enzyme and produced by the adrenal zona glomerulosa ...
Alessio Mazzieri, Francesca Timio, Francesco Patera, Francesco Trepiccione, Mario Bonomini, Gianpaolo Reboldi   +5 more
doaj   +1 more source

New clinical opportunities for mineralocorticoid receptor antagonists: focus on antifibrotic effects

Терапевтический архив, 2021
Mineralocorticoid receptor antagonists have been successfully used for many years to treat patients with primary hyperaldosteronism, refractory arterial hypertension and chronic heart failure. The increased interest in this drug in recent years is due to
Natalia A. Dragomiretskaya, Aida I. Tarzimanova, Julia S. Kucherova, Valery I. Podzolkov   +3 more
doaj   +1 more source

ACTH Antagonists. [PDF]

, 2016
Adrenocorticotropin (ACTH) acts via a highly selective receptor that is a member of the melanocortin receptor subfamily of type 1 G protein-coupled receptors.
Attard, Beardwell, Biller, Boscaro, Bouw, Capatina, Chretien, Chung, Clark, Clark, Colao, Cooray, Cooray, Dores, Draper, Eberle, Fani, Feldhaus, Fridmanis, Goverde, Halem, Han, Hofmann, Hofmann, Joint LWPES/ESPE CAH Working Group, Juszczak, Keller-Wood, Kola, Kovalitskaia, Li, Liang, Lim, Lorimer, Lowry, Malik, Metherell, Miller, Mountjoy, Nensey, Nimkarn, Noon, Osborne, Peri, Pogozheva, Ramachandrappa, Ryan, Samuels, Schwyzer, Schwyzer, Schwyzer, Schöneshöfer, Sebag, Seelig, Seelig, Seferovic, Siepler, Singh, Sonino, Szalay, Veo, Verhelst, Webb, Yang, Zhu   +63 more
core   +3 more sources

MELD score predicts outcomes in patients with advanced heart failure: A longitudinal evaluation

ESC Heart Failure, Volume 12, Issue 2, Page 839-847, April 2025.
Abstract Aims Advanced heart failure (AHF) is characterized by recurrent episodes of haemodynamic instability and frequent hospitalizations, leading to a progressive decline in quality of life and high mortality rates. The objectives of this study were to evaluate the effect of the model for end‐stage liver disease (MELD) score and its variations in ...
Francesco Curcio, Cristiano Amarelli, Rosaria Chiappetti, Irene Mattucci, Veronica Flocco, Mahmoud Issa Rammal, Ciro Abete, Francesca Mazzella, Ciro Maiello, Pasquale Abete, Francesco Cacciatore   +10 more
wiley   +1 more source

A COMPARATIVE ASSESSMENT OF THE EFFECT OF MINERALOCORTICOID RECEPTOR ANTAGONISTS ON CHANGES IN GALECTIN-3 AND MMP-1 FIBROSIS MARKERS IN PATIENTS WITH CHRONIC CARDIAC FAILURE COMBINED WITH TYPE 2 DIABETES MELLITUS WITH MANIFESTATIONS OF MYOCARDIUM DYSSYNCHRONY

Journal of V. N. Karazin Kharkiv National University: Series Medicine, 2016
A comparative assessment of the effect of mineralocorticoid receptor antagonists on changes in galectin 3 and matrix metalloproteinase 1 fibrosis markers has been carried out on 106 examinations (average age (69 + 10.37) years) with type 2 DM and CCF of ...
T. A. Rudenko
doaj  

Hormone treatments in congestive heart failure

Journal of International Medical Research, 2018
The common ultimate pathological feature for all cardiovascular diseases, congestive heart failure (CHF), is now considered as one of the main public health burdens that is associated with grave implications. Neurohormonal systems play a critical role in
Lei Lei, Yuanjie Mao
doaj   +1 more source

Carbonyl reductase 1 amplifies glucocorticoid action in adipose tissue and impairs glucose tolerance in lean mice

Molecular Metabolism, 2021
Objective: Carbonyl reductase 1 (Cbr1), a recently discovered contributor to tissue glucocorticoid metabolism converting corticosterone to 20β-dihydrocorticosterone (20β-DHB), is upregulated in adipose tissue of obese humans and mice and may contribute ...
Rachel M.B. Bell, Elisa Villalobos, Mark Nixon, Allende Miguelez-Crespo, Lee Murphy, Angie Fawkes, Audrey Coutts, Matthew G.F. Sharp, Martha V. Koerner, Emma Allan, Onno C. Meijer, Renè Houtman, Alex Odermatt, Katharina R. Beck, Scott G. Denham, Patricia Lee, Natalie Z.M. Homer, Brian R. Walker, Ruth A. Morgan   +18 more
doaj   +1 more source